Table 5.
Baseline characteristics of progressive and non-progressive patients at year 10, based on analysis of change in EDSS score from year 1 (induction treatment termination).
| Baseline Characteristics | Non-Progressive (n = 5) |
Progressive (n = 21) |
p-Value |
|---|---|---|---|
| Gender (female/male) | 5/0 | 14/7 | >0.05 |
| Age at treatment initiation, years (mean ± SD) | 32.8 ± 2.6 | 35.3 ± 6.4 | >0.05 |
| Disease duration to treatment initiation, years (mean ± SD) |
8.1 ± 3.8 | 9.1 ± 2.1 | >0.05 |
| Cladribine (s.c.) cumulative dose at year 10 (mg/kg body weight; mean ± SD) |
3.2 ± 1.0 | 2.3 ± 1.0 | 0.01 |
| EDSS score at cladribine initiation (mean ± SD) | 4.2 ± 1.4 | 3.7 ± 1.2 | 0.05 |
EDSS, Expanded Disability Status Scale; n, number of patients; s.c., subcutaneous; SD, standard deviation.